Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05111613 · ClinicalTrials.gov registry record · NA
The PEERLESS Study
A NA study, sponsored by Inari Medical.
- Completed
- Registry status
- NA
- Development phase
- 692
- Enrollment target
NCT05111613 is a NA study that has completed, run by Inari Medical. The registered enrollment target is 692 participants.
The verdict
NCT05111613, a NA study, has completed, sponsored by Inari Medical.
- COMPLETED
- Registry status
- NA
- Development phase
- 692 participants
- Enrollment target
Study Summary
A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
Interventions
- DEVICE FlowTriever System
- DEVICE Catheter-Directed Thrombolysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 692 participants |
| Start Date | 2022-02-14 |
| Est. Completion | 2024-04-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05111613
The ClinicalTrials.gov registry entry for NCT05111613 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 692 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Inari Medical, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which FlowTriever System is the first listed.
NCT05111613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05111613 about?
NCT05111613 is a clinical study titled "The PEERLESS Study". A prospective, multicenter, randomized controlled trial of the FlowTriever System compared to Catheter-Directed Thrombolysis (CDT) for use in the treatment of acute pulmonary embolism. The trial includes a non-randomized cohort of subjects with an absolute contraindication to thrombolysis.
What is the current status of trial NCT05111613?
This trial is currently completed. It is a NA study. The enrollment target is 692 participants. The study started on 2022-02-14. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT05111613?
The interventions under investigation include: FlowTriever System (DEVICE), Catheter-Directed Thrombolysis (DEVICE).
Who is sponsoring clinical trial NCT05111613?
This trial is sponsored by Inari Medical, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.